We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Investor Suit Against Dendreon Can Proceed

Law360 (May 21, 2009, 12:00 AM EDT) -- A federal court has allowed an investor class action alleging that Dendreon Corp. and its officers deceived investors about the approval process for its experimental advanced prostate cancer drug Provenge to continue.

The U.S. District Court for the Western District of Washington on Thursday denied a motion to dismiss most claims of the suit against Dendreon, its CEO Mitchell Gold and its Chief Science Officer David Urdal. However, the court did dismiss claims against Urdal under Section 10(b) of the Securities Exchange Act.

The order did...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.